Publication date: Jan 18, 2025

We previously reported the safety and immunogenicity data from a randomized trial comparing the booster responses of vaccinees who received monovalent (MV) recombinant protein Beta-variant (MVB. 1.351) and MV ancestral protein (MVD614) vaccines with AS03 adjuvant (Sanofi/GSK) to booster response of vaccinees who received mRNA MV ancestral strain BNT162b2 vaccine (Pfizer-BioNTech). First booster of the vaccines was administered in adult participants previously primed with 2 doses of MV ancestral strain BNT162b2. A subset of these participants with available blood samples collected at Day 0 (D0), at 28 days (D28), and 3 months (M3) post-booster were contacted for additional testing (195/208 participants). The persistence of cross-neutralizing antibodies, including against Omicron BA. 1 and BA. 4/5, up to 3 months after boosting was evaluated using a validated pseudovirus neutralization assay. Across the whole population, MVB. 1.351 vaccine induces highest NAbs titers against Omicron BA. 1 and BA. 4/5 variants at D28 and M3 post-booster. In participants with SARS-CoV-2 infection between D28 and M3, both MVB. 1.351 and BNT162b2 vaccine groups show an increase in GMTs against Omicron BA. 1 and Omicron BA. 4/5 following infection. Among uninfected participants, the ratio of M3 to D28 GMTs was higher for the MVB. 1.351 group than the BNT162b2 group against Omicron BA. 1 (0. 64 [0. 53;0. 77] versus 0. 43 [0. 35;0. 53]), Omicron BA. 4/5 (0. 61 [0. 50; 0. 75] versus 0. 44 [0. 34; 0. 56]), and D614 (0. 68 [0. 58,0. 81] versus 0. 46 [0. 39,0. 55]). The MVB. 1.351 vaccine induces higher and durable cross-neutralizing antibodies against Omicron subvariants up to 3 months after boosting compared to an MV ancestral and mRNA BNT162b2 booster vaccine.

Semantics

Original Article